➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Colorcon
Dow
McKinsey
Medtronic

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

THALLOUS CHLORIDE TL 201 Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Thallous Chloride Tl 201, and when can generic versions of Thallous Chloride Tl 201 launch?

Thallous Chloride Tl 201 is a drug marketed by Bracco, Curium, Ge Healthcare, Lantheus Medcl, and Trace Life. and is included in six NDAs.

The generic ingredient in THALLOUS CHLORIDE TL 201 is thallous chloride tl-201. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the thallous chloride tl-201 profile page.

Summary for THALLOUS CHLORIDE TL 201
Drug patent expirations by year for THALLOUS CHLORIDE TL 201
Pharmacology for THALLOUS CHLORIDE TL 201

US Patents and Regulatory Information for THALLOUS CHLORIDE TL 201

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INJECTION 018548-001 Dec 30, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Lantheus Medcl THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INTRAVENOUS 017806-002 Oct 9, 1998 DISCN Yes No   Start Trial   Start Trial   Start Trial
Lantheus Medcl THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INJECTION 017806-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Curium THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INJECTION 018150-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Ge Healthcare THALLOUS CHLORIDE TL 201 thallous chloride tl-201 INJECTABLE;INJECTION 018110-002 Feb 27, 1996 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Dow
Moodys
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.